Health Care & Life Sciences » Pharmaceuticals | Schnell Biopharmaceuticals Inc.

Schnell Biopharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
29,543
33,092
40,324
44,122
46,101
45,395
Cost of Goods Sold (COGS) incl. D&A
21,076
22,749
25,761
25,348
27,298
26,340
Gross Income
8,467
10,343
14,563
18,774
18,803
19,055
SG&A Expense
23,611
15,782
15,151
18,721
25,119
19,623
EBIT
15,938
5,738
956
247
6,913
1,020
Unusual Expense
4,267
1,470
732
145
475
3,030
Non Operating Income/Expense
182
250
2,939
253
1,270
5,850
Interest Expense
318
1,346
295
4,186
9,135
7,405
Pretax Income
20,042
4,604
1,390
4,051
16,524
952
Income Tax
-
19
337
716
367
263
Equity in Affiliates
810
227
175
-
-
-
Consolidated Net Income
20,852
4,396
1,553
4,767
16,891
1,215
Net Income
20,852
3,887
2,761
3,918
16,365
1,215
Net Income After Extraordinaries
20,852
3,887
2,761
3,918
16,365
1,215
Net Income Available to Common
20,852
3,887
2,761
3,918
16,365
1,215
EPS (Basic)
338.00
56.00
35.00
48.00
201.00
10.20
Basic Shares Outstanding
62
70
79
81
82
119
EPS (Diluted)
338.98
55.15
34.76
48.49
200.58
10.20
Diluted Shares Outstanding
62
70
79
81
82
119
EBITDA
15,148
4,351
644
1,092
5,260
442
Other Operating Expense
794
299
368
301
597
453
Non-Operating Interest Income
662
760
434
489
1,938
2,583
Minority Interest Expense
-
509
1,208
849
526
-
Equity in Affiliates (Pretax)
-
-
-
-
4,158
2,068

About Schnell Biopharmaceuticals

View Profile
Address
Room 301 Gangho Building
Seoul SL 06735
Korea, Republic Of
Employees -
Website http://www.aprogen-pharm.com
Updated 07/08/2019
Aprogen Pharmaceuticals, Inc. engages in the manufacture and sale of pharmaceutical products. It operates throught the Pharmaceutical Manufacturing and Wholesale business divisions. The Pharmaceutical Manufacturing division provides antibiotics, antirhematics, and medicines for dermatopathy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.